• The Lancet Respiratory Medicine in conversation with

  • 著者： The Lancet Group
  • ポッドキャスト

The Lancet Respiratory Medicine in conversation with

著者： The Lancet Group
無料で聴く

  • サマリー

  • Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
    © 2025 The Lancet Group
    続きを読む 一部表示

あらすじ・解説

Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
© 2025 The Lancet Group
生物科学 科学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • Sandeep Sahay and Franck Rahaghi on future treatment paradigms in pulmonary arterial hypertension

    Sandeep Sahay and Franck Rahaghi on future treatment paradigms in pulmonary arterial hypertension
    2025/02/19

    Dr Sandeep Sahay and Professor Franck Rahaghi discuss their Personal View on future treatment paradigms in pulmonary arterial hypertension.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    15 分
  • Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)

    Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)
    2024/10/25

    Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    11 分
  • Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

    Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
    2024/10/25

    Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    10 分
activate_buybox_copy_target_t1

The Lancet Respiratory Medicine in conversation withに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。